Business
CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits
MONMOUTH JUNCTION, N.J., March 2, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader commercializing its blood
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., March 2, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights the recent publication entitled, \"Intraoperative hemoadsorption in patients with native mitral valve endocarditis,\" in the journal, The Annals of Thoracic Surgery.\n\n \n \n \n \n \n \n\n \nIn this retrospective study, Dr. Zaki Haidari, MD and colleagues at the West-German Heart and Vascular Center of the University Hospital Essen, Germany investigated whether intraoperative CytoSorb® hemoadsorption could improve surgical outcomes in patients with infective endocarditis (i.e. infection of the heart valve) undergoing surgical replacement or repair of their diseased mitral heart valve. The authors retrospectively identified 58 consecutive patients, 30 of which were treated with CytoSorb therapy (CytoSorb group) and 28 that were not (control group), that underwent surgery from January 2014 to July 2017. There were no statistically significant differences between the two groups in terms of baseline demographics, hemodynamic or pulmonary instability, and levels of preoperative inflammatory parameters. The post-operative need of vasopressors to support blood pressure, as well as the incidence of post-operative sepsis, sepsis-associated death, and 30-day mortality, were compared.\nKey study findings in those receiving intraoperative CytoSorb hemoadsorption included:\nImproved postoperative hemodynamic stability at ICU-admission. Postoperatively, at ICU admission, the overall need for epinephrine and norepinephrine was 0.15 versus 0.24 μg/kg BW/min (p=0.01) and the median systemic vascular resistance was 1,413 versus 1,010 dyn·s·cm-5 (p=0.02) in the CytoSorb versus control group, respectively. Postoperative sepsis was less frequent. As defined by the Third International Consensus Definition of Sepsis, postoperative sepsis occurred in 16.7% (5/30) in the CytoSorb group versus 39.3% (11/28) of control patients (p=0.05). Significant reduction in sepsis-associated deaths. No sepsis-associated deaths (0/30) occurred in the CytoSorb group, while 17.9% (5/28) of patients died from refractory septic shock in the control group (p=0.02). Trend to improved 30-day ...